1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Real-Time PCR (q-PCR)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Next-Generation Sequencing (NGS)
1.2.5 Fluorescent In-Situ Hybridization (FISH)
1.3 Market by Application
1.3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Perspective (2017-2028)
2.2 Next-Generation Breast Cancer Diagnostic and Screening Growth Trends by Region
2.2.1 Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Region (2017-2022)
2.2.3 Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Region (2023-2028)
2.3 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics
2.3.1 Next-Generation Breast Cancer Diagnostic and Screening Industry Trends
2.3.2 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
2.3.3 Next-Generation Breast Cancer Diagnostic and Screening Market Challenges
2.3.4 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue
3.1.1 Global Top Next-Generation Breast Cancer Diagnostic and Screening Players by Revenue (2017-2022)
3.1.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Players (2017-2022)
3.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Next-Generation Breast Cancer Diagnostic and Screening Revenue
3.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio
3.4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2021
3.5 Next-Generation Breast Cancer Diagnostic and Screening Key Players Head office and Area Served
3.6 Key Players Next-Generation Breast Cancer Diagnostic and Screening Product Solution and Service
3.7 Date of Enter into Next-Generation Breast Cancer Diagnostic and Screening Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Type (2017-2022)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Type (2023-2028)
5 Next-Generation Breast Cancer Diagnostic and Screening Breakdown Data by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Historic Market Size by Application (2017-2022)
5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
6.2.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
6.2.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
6.2.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
6.3.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
6.3.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
6.4 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
6.4.1 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
6.4.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
7.2.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
7.2.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
7.2.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
7.3.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
7.3.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
7.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
7.4.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
7.4.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
8.2.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
8.4 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
8.4.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
9.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
9.2.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
9.2.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
9.2.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
9.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
9.3.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
9.3.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
9.3.3 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
9.4 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
9.4.1 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
9.4.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size (2017-2028)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type
10.2.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Type (2017-2028)
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application
10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Share by Application (2017-2028)
10.4 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
10.4.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.1.4 Abbott Laboratories Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.1.5 Abbott Laboratories Recent Developments
11.2 Agendia
11.2.1 Agendia Company Details
11.2.2 Agendia Business Overview
11.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.2.4 Agendia Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.2.5 Agendia Recent Developments
11.3 Agilent Technologies
11.3.1 Agilent Technologies Company Details
11.3.2 Agilent Technologies Business Overview
11.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.3.4 Agilent Technologies Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.3.5 Agilent Technologies Recent Developments
11.4 Ambry Genetics
11.4.1 Ambry Genetics Company Details
11.4.2 Ambry Genetics Business Overview
11.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.4.4 Ambry Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.4.5 Ambry Genetics Recent Developments
11.5 Biocept
11.5.1 Biocept Company Details
11.5.2 Biocept Business Overview
11.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.5.4 Biocept Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.5.5 Biocept Recent Developments
11.6 Biotheranostics
11.6.1 Biotheranostics Company Details
11.6.2 Biotheranostics Business Overview
11.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.6.4 Biotheranostics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.6.5 Biotheranostics Recent Developments
11.7 Centogene
11.7.1 Centogene Company Details
11.7.2 Centogene Business Overview
11.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.7.4 Centogene Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.7.5 Centogene Recent Developments
11.8 Danaher Corporation
11.8.1 Danaher Corporation Company Details
11.8.2 Danaher Corporation Business Overview
11.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.8.4 Danaher Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.8.5 Danaher Corporation Recent Developments
11.9 EXACT Sciences Corporation
11.9.1 EXACT Sciences Corporation Company Details
11.9.2 EXACT Sciences Corporation Business Overview
11.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.9.4 EXACT Sciences Corporation Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.9.5 EXACT Sciences Corporation Recent Developments
11.10 Roche Holding AG
11.10.1 Roche Holding AG Company Details
11.10.2 Roche Holding AG Business Overview
11.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.10.4 Roche Holding AG Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.10.5 Roche Holding AG Recent Developments
11.11 Fulgent Genetics
11.11.1 Fulgent Genetics Company Details
11.11.2 Fulgent Genetics Business Overview
11.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.11.4 Fulgent Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.11.5 Fulgent Genetics Recent Developments
11.12 Illumina
11.12.1 Illumina Company Details
11.12.2 Illumina Business Overview
11.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.12.4 Illumina Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.12.5 Illumina Recent Developments
11.13 Invitae
11.13.1 Invitae Company Details
11.13.2 Invitae Business Overview
11.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.13.4 Invitae Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.13.5 Invitae Recent Developments
11.14 Lucence Diagnostics Pte Ltd
11.14.1 Lucence Diagnostics Pte Ltd Company Details
11.14.2 Lucence Diagnostics Pte Ltd Business Overview
11.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.14.4 Lucence Diagnostics Pte Ltd Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.14.5 Lucence Diagnostics Pte Ltd Recent Developments
11.15 Myriad Genetics
11.15.1 Myriad Genetics Company Details
11.15.2 Myriad Genetics Business Overview
11.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Introduction
11.15.4 Myriad Genetics Revenue in Next-Generation Breast Cancer Diagnostic and Screening Business (2017-2022)
11.15.5 Myriad Genetics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
